Ospedale Santa Maria Annunziata — Clinical Trial Site

10 Registered trials

5 Currently recruiting

Organisation

Ospedale Santa Maria Annunziata

Location

Bagno A Ripoli, Italy

Identifier

ORG-100041775

Address

Via Dell' Antella 58, 50012, Italy

Departments

Dipartimento Oncologico
Dipartimento Oncologico - S.O.C. Oncologia Medica
Infectious Diseases
Medical oncology
Nefrologia
Nephrology
Neurologia e Stroke Unit
Oncology department
SOC Malattie Infettive I

Clinical trials at this site (10)

Search interface

A PROJECT FOR TWO MULTICENTRE, PROSPECTIVE OPEN LABEL RANDOMIZED CLINICAL STUDIES TO EVALUATE THE EFFECT OF TARGETED THERAPY BASED ON KIDNEY… Pending

2024-517861-18-00 Idiopathic IgA nephropathy (IgAN) 5
Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFI… Recruiting

2024-517863-22-00 Study population consists in patients with a diagnosis 5 2024-12-01
A Study to Evaluate the Efficacy and Safety of XyloCore, a Glucose Sparing Experimental Solution, for Peritoneal Dialysis (ELIXIR) Recruiting

2024-513562-19-00 End-Stage Kidney Disease 5 2023-08-30
Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3) Recruiting

2022-500587-35-01 Stroke 5 2023-07-06
ExclUsive endocRine therapy Or radiation theraPy for women aged ≥70 years with luminal A-like early stage breast cancer (EUROPA): a randomiz… Recruiting

2023-508094-88-00 breast cancer 5 2021-02-08
“A phase II randomized non-comparative study, with NEOadjuvant plus adjuvant Therapy with combination or sequence of vemurafenib, cobImetini… Recruiting

2024-516659-41-00 high-risk, surgically resectable BRAF mutated and wild- 4 2020-10-12
Early DOlutegravir/LAmivudine Switching after virological suppression (EDOLAS Study) Ended

2024-518909-18-00 HIV-1 infected individuals currently taking an INSTI-ba 5 2021-03-23
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant versus Placebo Plus Palbociclib and Fulvestrant in… Ended

2023-505812-39-00 HR+/HER2-Negative Locally Advanced or Metastatic Breast 5 2020-08-28
Efficacy and Safety of AXL-Inhibitor bemcentinib for the Treatment of Moderate COVID-19 (AXL-SolidAct) Ended

2022-500363-12-00 SARS CoV-2 (COVID-19) 4 2022-08-24
European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial (SolidAct) Ended

2022-500385-99-00 SARS-CoV II infection (Coronavirus disease) 5 2021-06-03